论文部分内容阅读
Galiximab(IDEC-144)是一种猴源性的、抗CD80(B7-1)IgG1的单克隆抗体,包含短尾猴IgG1的可变区和人IgG1的恒定区。本品由美国Biogen Idec公司研制,并在研制中使用了一项名为PRIMATIZED的抗体技术以降低免疫原性。体外实验表明,本品的抗肿瘤活性与抗体依赖性细胞介导的细胞毒作用
Galiximab (IDEC-144) is a monkey-derived, monoclonal antibody against CD80 (B7-1) IgG1, comprising the variable region of cynomolgus IgG1 and the constant region of human IgG1. This product by the United States Biogen Idec company developed and used in the development of a called PRIMATIZED antibody technology to reduce the immunogenicity. In vitro experiments show that the anti-tumor activity of this product and antibody-dependent cell-mediated cytotoxicity